参考文献/References:
[1] Kannel WB, Wolf PA, Benjamin EJ, et al.Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates[J].Am J Cardiol,1998,82:2N-9N.
[2] Carom AJ, Lip GY, de Caterina R, et al.2012 focused update of the ESC guidelines for the management of atrial fibrillation:an update of the 2010 ESC guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J,2012,33(21):2719-2747.
[3] January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21):e1-76.
[4] Ruff CT, Giugliano RP, Antman EM, et al.Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation:design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48(ENGAGE AF-TIMI 48)[J].Am Heart J,2010,160(4):635-641.
[5] Partida RA, Giugliano RP.Edoxaban:pharmacological principles, preclinical and early-phase clinical testing[J].Future Cardiol,2011,7(4):459-470.
[6] Bounameaux H, Camm AJ.Edoxaban:an update on the new oral direct factor Xa inhibitor[J].Drugs,2014,74(11):1209-1231.
[7] Ogata K,Mendell-Harary J,Tachibana M,et al.Clinical safety,tolerability,pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers[J].J Clin Pharmacol,2010,50(7):743-753.
[8] Yin OQ, Tetsuya K, Miller R.Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation[J].Eur J Clin Pharmacol,2014,70(11):1339-1351.
[9] Mendell J, Tachibana M, Shi M,et al.Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers[J].J Clin Pharmacol,2011,51(5):687-694.
[10] Mikkaichi T, Yoshigae Y, Masumoto H,et al.Edoxaban transport via P-glycoproteinis a key factor for the drug's disposition[J].Drug Metab Dispos, 2014,42(4):520-528.
[11] Plitt A, Giugliano RP.Edoxaban:review of pharmacology and key phase Ⅰ to Ⅲ clinical trials[J].J Cardiovasc Pharmacol Ther, 2014,19(5):409-416.
[12] Zafar MU, Vorchheimer DA, Gaztanaga J,et al.Antithrombotic effects of factor Xa inhibition with DU-176b:phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber[J].Thromb Haemost,2007,98(4):883-888.
[13] Weitz JI, Connolly SJ, Patel I, et al.Randomised, parallel-group, multicentre,multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation[J].Thromb Haemost,2010,104(3):633-641.
[14] Song S, Kang D, Halim AB,et al.Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment[J].J Clin Pharmacol,2014,54(8):910-916.
[15] Mendell J, Zahir H, Matsushima N, et al.Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor[J].Am J Cardiovasc Drugs,2013,13(5):331-342.
[16] Mendell J, Noveck RJ, Shi M.Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination[J].J Cardiovasc Pharmacol, 2012,60(4):335-341.
[17] Salazar DE, Mendell J, Kastrissios H, et al.Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation[J].Thromb Haemost, 2012,107(5):925-936.
[18] Mendell J, Lee F, Chen S, et al.The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor[J].J Cardiovasc Pharmacol, 2013,62(2):212-221.
[19] Chung N, Jeon HK, Lien LM, et al.Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation[J].Thromb Haemost, 2011,105(3):535-544.
[20] Yamashita T, Koretsune Y, Yasaka M, et al.Randomized, multicenter,warfarin-controlled phase Ⅱ study of edoxaban in Japanese patients with nonvalvular atrial fibrillation[J].Circ J, 2012,76(8):1840-1847.
[21] Giugliano RP, Ruff CT, Braunwald E, et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[22] Giugliano RP, Ruff CT, Rost NS, et al.Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48[J].Stroke, 2014,45(8):2372-2378.
[23] Rost NS, Giugliano RP, Ruff CT, et al.Efficacy and safety of edoxaban vs.warfarin in high-risk patients: the ENGAGEAF-TIMI 48 trial[C].Presented at 9TH World Stroke Congress 22-25 October, Istanbul Turkey,Abstract WSC-1119 2014.
[24] Kato ET, Giugliano RP, Ruff CT, et al.Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48[J].Circulation, 2014,130:A16612.
[25] Xu H, Ruff CT, Giugliano RP, et al.Concomitant use of antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial[J].Circulation,2014,130:A19119.
[26] Chen JY, Zhuang XD, Long M, et al.Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials[J].J Stroke Cerebrovasc Dis,2015,24(12):2710-2719.
[27] Lu G, DeGuzman FR, Hollenbach SJ, et al.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa[J].Nat Med,2013,19(4):446-451.
[28] Fukuda T, Honda Y, Kamisato C, et al.Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor,with haemostatic agents[J].Thromb Haemost,2012,107(2):253-259.
[29] Brown KS,Wickremasingha P, Dolly A, et al.The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban[J].Thromb Res,2015,136(4):825-831.
[30] Zahir H, Brown KS, Vandell A, et al.Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate[J].Circulation,2015,131(1):82-90.
[31] Ansell JE, Bakhru SH, Laulicht BE, et al.Use of PER977 to reverse the anticoagulant effect of edoxaban[J].N Engl J Med,2014,371(22):2141-2142.
[32] Laliberte F, Nelson WW, Lefebvre P, et al.Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients[J].Adv Ther,2012,29(8):675-690.
[33] Blann AD, Banerjee A, Lane DA, et al.Net clinical benefit of edoxaban versus no treatment in a ‘real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study[J].Int J Cardiol,2015,201:693-698.
[34] Rognoni C, Marchetti M, Quaglini S,et al.Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis[J].J Thromb Thrombolysis,2015,39(2):149-154.
[35] Krejczy M, Harenberg J, Wehling M, et al.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany[J].Biomed Res Int,2015,2015:876923.
[36] Hokusai-VTE Investigators.Büller HR, Décousus H, et al.Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J].N Engl J Med,2013,369(15):1406-1415.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(2):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(2):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[5]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[6]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(2):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[7]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[8]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(2):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[9]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
[10]夏平,杨浩.炎症与心房颤动相关性的研究进展[J].心血管病学进展,2015,(5):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
XIA Ping,YANG Hao.Research Progress of Inflammation Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
[11]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(2):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[12]蒋靖波,钟国强.心房颤动导管消融中脑卒中和无症状脑梗死的预防[J].心血管病学进展,2015,(6):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]
JIANG Jingbo,ZHONG Guoqiang.Strategies to Prevent Periprocedural Stroke and Subclinical Cerebral Emboli in
Patients Undergoing Catheter Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):743.[doi:10.3969/j.issn.1004-3934.2015.06.022]